Overview
- The TTAM Research Institute’s $305 million offer outstripped Regeneron’s $256 million bid and covers 23andMe’s genetic testing and telehealth operations
- The sale hinges on approval by the U.S. Bankruptcy Court for the Eastern District of Missouri, with a decision expected following the June 17 hearing
- More than two dozen states have lodged objections or lawsuits to block the transfer of consumer genome data over privacy and security concerns
- Roughly 1.9 million customers—about 15% of the user base—have requested deletion of their data since the March bankruptcy filing after a 2023 breach exposed 7 million accounts
- TTAM has committed to uphold existing privacy policies, comply with data protection laws and establish a consumer privacy advisory board